CurrentPremera BluecrossPolicy N/A

Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Defines medical necessity and investigational status for allogeneic and autologous hematopoietic cell transplantation in individuals with chronic myeloid leukemia; intended for providers and payers assessing coverage.

Policy Summary

PayerPremera Bluecross

PolicyAllogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateApr 1, 2026

Key ActionObtain prior authorization and submit documentation showing diagnosis, prior TKI therapy and response, and clinical indications consistent with NCCN guidance.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

NCCN v1.2026guideline cited

Investigationalautologous stance

Codes addedcoding update

No NCDMedicare NCD

Coverage Criteria for Hematopoietic Cell Transplantation (CML)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Allogeneic HCT - myeloablative

Indications include TKI failure or resistance, TKI intolerance, disease progression to accelerated phase or blast phase, or other clinical considerations per NCCN recommending evaluation for allo-HCT in AP or BP CML.
Refer to NCCN v1.2026 guidance.

Allogeneic HCT - reduced-intensity: Allogeneic hematopoietic cell transplantation using a reduced-intensity conditioning regimen may be considered medically necessary for individuals meeting clinical criteria for allo-HCT who are not candidates for myeloablative conditioning (e.g., older age >60 years or significant comorbidities).

Reduced-intensity intended for nonmyeloablative regimens; may be used for those >60 or with organ dysfunction or low performance status.

Investigational Coverage Stance

Not covered / Investigational

Autologous HCT: Autologous hematopoietic cell transplantation is considered investigational as a treatment of chronic myeloid leukemia.

Evidence insufficient to determine improvement in net health outcome; available evidence primarily case series.

Allogeneic HCT - NCCN-aligned indications

Covered when ANY of the following NCCN-recommended indications are met:

NCCN allo-HCT indications: Allogeneic HCT is appropriate for: (1) chronic-phase CML resistant and/or intolerant to all available TKIs; (2) disease progression to accelerated phase CML during TKI therapy; (3) blast phase CML patients who achieve morphologic remission; and (4) evaluation is recommended for all patients with AP or BP CML.N/A

Autologous HCT not addressed by NCCN

State mandates, plan-specific contract provisions, or participation in certain voluntary programs may supersede this policy. Examples include state mandates requiring coverage for autologous bone marrow transplantation offered as part of NIH‑approved clinical trials, participation in voluntary programs that provide coverage for individuals in NIH‑approved cancer clinical trials, or specific contract/certificate provisions that define situations in which autologous bone marrow transplantation is eligible for coverage.

Use of allogeneic hematopoietic cell transplantation (allo‑HCT) outside NCCN‑indicated settings — for example, in chronic‑phase CML that is not resistant or intolerant to available TKIs, or in cases that have not progressed to accelerated phase during TKI therapy and are not blast phase achieving remission — is not supported by the cited guideline recommendations and is considered not covered / investigational under this policy.

Provider Requirements, Authorization, and Documentation

Prior Authorization

Code-based authorization — Prior authorization should reference applicable procedure and HCPCS codes

Prior authorization is required and must reference the applicable procedure and HCPCS/CPT codes for bone marrow/hematopoietic progenitor cell harvesting and transplantation.

Include the specific CPT/HCPCS codes on the PA request and claim: 38230, 38232, 38240, 38241; HCPCS S2142, S2150.

Documentation Required

Required clinical documentation

The individual's medical records submitted for review must document that medical necessity criteria are met. Lack of sufficient documentation may result in denial of the request.

Required documentation must include diagnosis/condition and history and physical documenting severity.
If documentation does not demonstrate the required clinical criteria (including prior treatments and response), the request may be denied.

Step Therapy

TKI therapy before transplant — TKIs are first-line; allo-HCT considered for TKI failure/intolerance/progression

Prior tyrosine kinase inhibitor (TKI) therapy and sequencing must be documented when allo-HCT is being considered for CML. TKIs are first-line for chronic phase CML; allo-HCT is considered for TKI failure, intolerance, progression to accelerated or blast phase, or specific high-risk scenarios.

Document trials of appropriate TKIs (e.g., imatinib, dasatinib, nilotinib, bosutinib, ponatinib) including doses, durations, responses, and reasons for discontinuation (resistance or intolerance).
If BCR-ABL variant testing (e.g., T315I) influenced decision for allo-HCT, include results and interpretation.

Documentation Required

Prior TKI therapy documentation — Treatment sequencing expectation: allo-HCT recommended after resistance/intolerance to available TKIs or for AP/BC transitions

When prior TKI therapy is relevant to the transplant decision, include sequencing rationale showing that allogeneic HCT is being pursued after resistance or intolerance to available TKIs or for progression to accelerated- or blast-phase disease.

State the sequence of therapies tried, objective measures of response (molecular, cytogenetic, hematologic), and dates of progression or treatment failure.
If allo-HCT is pursued despite limited TKI attempts, provide clinical rationale and supporting documentation.

Note

Medicare coverage absence — Absence of an NCD does not itself authorize service

Absence of a Medicare National Coverage Determination (NCD) does not itself authorize coverage. The lack of an NCD may affect prior authorization adjudication; benefits remain subject to the member's contract and this policy.

Confirm member-specific benefits and limits in the benefit booklet or with customer service; this policy does not apply to Medicare Advantage.
Do not assume coverage solely because no NCD exists; submit full clinical documentation for PA review.

Denial Risk

Documentation insufficiency — Lack of documentation of medical necessity criteria may trigger denial

Insufficient or missing documentation of the medical necessity criteria (diagnosis, history and physical, prior therapies and responses, and relevant test results) may result in denial of prior authorization requests.

Ensure submitted records include diagnosis, H&P, treatment history (including TKIs), response assessments, and test results (e.g., BCR-ABL mutation testing).
If additional information is requested, timely submission is required for continued consideration.

Documentation Required

Clinical indication documentation — Documentation should support indications consistent with NCCN

Documentation should explicitly support clinical indications consistent with NCCN recommendations for allo-HCT (for example: CP-CML resistant/intolerant to all available TKIs, progression to AP-CML during TKI therapy, or BP-CML achieving morphologic remission). Autologous HCT for CML is not addressed in NCCN guidance.

Cite specific NCCN-consistent indication on the request and include supporting evidence (mutation status, phase of disease, prior TKI responses).

Procedure and Billing Codes

CPT codes for harvesting and transplantationCPT

38230	Bone marrow harvesting for transplantation; allogeneic.
38232	Bone marrow harvesting for transplantation; autologous.
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
38241	Hematopoietic progenitor cell (HPC); autologous transplantation.

HCPCS codesHCPCS

S2142

Cord blood-derived stem-cell transplantation, allogeneic.

S2150

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition

Covered CPT and HCPCS Codes addedmixedCovered

38230	Harvesting of hematopoietic progenitor cells; peripheral blood
38232	Cell processing, separation, or purification
38240	Transplantation of hematopoietic progenitor cells; allogeneic (unrelated donor)
S2142	Hematopoietic progenitor cell collection (HCPCS) - code added
S2150	Autologous hematopoietic progenitor cell collection (HCPCS) - code added

Terms and Definitions

inv-19: Allogeneic HCT — definition and conditioning options (myeloablative, RIC)

DefinitionAllogeneic hematopoietic cell transplantation (allo-HCT): hematopoietic cell transplantation using donor-derived hematopoietic stem cells with consideration of HLA compatibility between donor and recipient.

Conditioning options — MyeloablativeTraditional full‑dose myeloablative conditioning uses high-dose cytotoxic drugs with or without whole‑body radiotherapy to ablate recipient marrow prior to donor cell infusion.

Conditioning options — Reduced‑intensity (RIC)Lower‑dose cytotoxic drug regimens or less intense radiotherapy intended to be nonmyeloablative (see separate RIC entry) and tailored based on age, comorbidity, and disease status.

HLA compatibility importanceImmunologic compatibility (HLA typing at HLA‑A, ‑B, and ‑DR loci) is critical in allo‑HCT to achieve successful engraftment and outcomes.

inv-20: Autologous HCT — definition and typical use

DefinitionAutologous hematopoietic cell transplantation: transplantation using the individual’s own harvested hematopoietic stem cells (bone marrow, peripheral blood, or cord blood).

Typical useTypically used as consolidation when disease is in complete remission; immunologic compatibility is not an issue because donor and recipient are the same individual.

Policy stance for CMLAutologous HCT is considered investigational for chronic myeloid leukemia (per this policy).

inv-21: Reduced-intensity conditioning (RIC) — definition and intent

DefinitionReduced‑intensity conditioning (RIC): pretransplant regimens using lower doses of cytotoxic drugs or less intense radiotherapy than traditional myeloablative regimens, intended to be nonmyeloablative.

IntentRIC seeks to reduce disease burden while minimizing treatment‑related morbidity and non‑relapse mortality during the period when graft‑versus‑malignancy effects develop.

Clinical tailoringRIC regimens vary in intensity from nearly myeloablative to minimally myeloablative with lymphoablation and are tailored to disease and individual patient condition (e.g., older age, comorbidities).

inv-22: Allogeneic HCT — concise term entry (alternate entry)

TermAllogeneic hematopoietic cell transplantation (allo‑HCT)

Synonym/contextDonor‑derived hematopoietic stem‑cell transplant with HLA matching considerations; may use myeloablative or reduced‑intensity conditioning depending on patient factors.

Source notePolicy discussion and definitions reference standard HCT concepts and conditioning options used in practice.

inv-23: TKI resistance/intolerance — definition/context for sequencing

Definition/contextTKI resistance or intolerance: failure to respond to, or inability to tolerate, available tyrosine kinase inhibitors used as first‑line therapy for chronic‑phase CML; this is a stated indication for consideration of allo‑HCT.

Sequencing implicationTKIs (e.g., imatinib and other TKIs) are first‑line for chronic‑phase CML; allo‑HCT is considered for patients resistant or intolerant to all available TKIs or with disease progression to accelerated or blast phase.

Documentation expectationPrior TKI therapy and response history should be documented when evaluating for allo‑HCT per policy and NCCN guidance.

Background and Regulatory Context

Chronic myeloid leukemia (CML) is a hematopoietic stem‑cell disorder characterized by the BCR‑ABL (Philadelphia) fusion that drives overproduction of myeloid cells and a clinical course that may progress from chronic phase (CP) to accelerated phase (AP) and blast phase (BP). Tyrosine kinase inhibitors (TKIs) are first‑line therapy for CP‑CML, but allogeneic hematopoietic cell transplantation (allo‑HCT) remains the only potentially curative option in high‑risk or advanced‑phase disease and for patients with TKI failure or intolerance. Conditioning regimens before allo‑HCT may be myeloablative or reduced‑intensity, with reduced‑intensity approaches used for older patients or those with significant comorbidities to balance relapse risk and nonrelapse mortality.

Hematopoietic stem cells and human cells/tissues intended for transplantation are regulated by the FDA Center for Biologics Evaluation and Research under 21 CFR parts 1270 and 1271, and hematopoietic stem cells are included in these regulations. Additionally, there is no Medicare national coverage determination (NCD) specific to these transplantation services.

References, Guidelines, and Revision History

This policy aligns with the NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia (v1.2026), which recommend evaluation for and consideration of allo‑HCT in high‑risk or advanced‑phase settings (CP‑CML resistant/intolerant to all available TKIs, progression to AP during TKI therapy, or BP achieving morphologic remission) and note that autologous HCT is not addressed. Supporting literature cited in the policy includes foundational and contemporary studies and reviews on CML diagnosis, TKI therapy, and transplantation outcomes (references 1–30), including long‑term follow‑up of imatinib, comparisons of TKIs, and multiple reports on allo‑HCT and reduced‑intensity conditioning outcomes.

2026-04-01policy_reviewLatest

Policy last reviewed and effective as of April 1, 2026; coding updates added to align CPT and HCPCS codes with policy criteria.

2026-03-09revision

Policy last revised March 9, 2026 (administrative and related policy cross-reference updates).

Policy Summary

PayerPremera Bluecross

PolicyAllogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateApr 1, 2026

Key ActionObtain prior authorization and submit documentation showing diagnosis, prior TKI therapy and response, and clinical indications consistent with NCCN guidance.

SourceLink

On This Page